CureDiab

CureDiab (CMR CureDiab Metabolic Research GmbH) is a biotechnology company based in Düsseldorf, Germany, specializing in the discovery and development of innovative treatments for metabolic disorders. As a spin-off from the German Diabetes Center (DDZ), the company focuses on a first-in-class therapeutic approach targeting the activation of the GABA-A ion channel to treat metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH). Its lead small molecule candidates exhibit dual anti-inflammatory and hepatoprotective properties, along with direct anti-fibrotic activity. Notably, these compounds have shown the potential to reduce weight without the loss of muscle mass in preclinical studies. CureDiab utilizes an AI-driven platform and advanced 3D liver-on-chip models to identify and validate drug candidates for systemic fibrosis across the liver, kidney, and heart. The company is currently in the pre-clinical stage and aims to transition its lead programs into clinical development through strategic partnerships or exits.